David Escalante, MD
Endocrinology, Diabetes & Metabolism · Jellico, TNNPI 1427096551
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $294,905 of the $326,296 with a category attached, or 90.4%. 42 manufacturers reported payments, led by Boehringer Ingelheim at 28.0% of the total. Reporting peaked in 2019 at $120,874 and has fallen 71.6% since, to $34,362 in 2025. Among endocrinology, diabetes & metabolism clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 886 payments — averaging $368.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$91K
- Sanofi-aventis U.S. LLC$85K
- Lilly USA, LLC$83K
- Corcept Therapeutics$47K
- AstraZeneca$10K
- Mannkind Corporation$6K
- plus $5K from 36 others
What the payments were for
- Consulting fees$5,3002%
- Speaking & faculty fees$294,90590%
- Travel & lodging$14,2914%
- Food & beverage$11,6454%
- Education$370%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$152,920
- SOLIQUA 100/33$67,865
- Korlym$44,391
- TOUJEO$15,779
- TRULICITY$13,116
- FARXIGA$9,718
- AFREZZA$5,397
- CeQur Simplicity$103
How this compares
$326,296 in reported general payments places this provider in the 90th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 43 | $1,762,270 |
| OzempicSemaglutide | 251 | $275,068 |
| IsturisaOsilodrostat Phosphate | 11 | $199,394 |
| TrulicityDulaglutide | 130 | $193,643 |
| MounjaroTirzepatide | 148 | $188,305 |
| JardianceEmpagliflozin | 140 | $116,242 |
| Tresiba Flextouch U-200Insulin Degludec | 102 | $106,405 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 72 | $91,106 |
| Humalog Kwikpen U-200Insulin Lispro | 49 | $89,202 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 61 | $64,407 |
| JanuviaSitagliptin Phosphate | 65 | $62,810 |
| FarxigaDapagliflozin Propanediol | 36 | $35,405 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 66 | $33,151 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $32,458 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $26,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $46,749 | $1,762,27043 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog Mix 75-25, Humalog | $82,735 | $401,764333 claims |
| Novo NordiskOzempic, Novolog, Rybelsus, Novolog Mix 70-30 | $317 | $305,668331 claims |
| Recordati_rare_diseases_inc.Isturisa | $259 | $199,39411 claims |
| Boehringer IngelheimJardiance | $91,382 | $116,242140 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $84,843 | $71,840101 claims |
| MerckJanuvia | $352 | $62,81065 claims |
| AstraZenecaFarxiga | $9,809 | $35,40536 claims |
| BayerKerendia | $125 | $12,30321 claims |
| AbbVieSynthroid | $550 | $6,516100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Jellico
- Alan CohenMemphis$1.4M
- Craig WierumNashville$1.3M
- Pascal DauphinHendersonville$925K
- Shimon HararyMemphis$735K
- Lisa MyersGermantown$609K
- Amit VoraKnoxville$579K
- Terri JerkinsNashville$567K
- Samuel Dagogo-JackMemphis$407K
- Michael CarlsonNashville$381K
- Kathryn DahirNashville$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.